Beijing Innocare Pharma Tech Co., Ltd.

Nanjing Innocare Pharma Tech Co., Ltd.

Zhixiang Zheng

Norman Xianglong Kong

Chao Zhou

The present invention relates to a compound, a pharmaceutical composition comprising the compound, the method for the preparation thereof, and the use thereof as TRK inhibitors. The compound is a compound as shown in the following formula I, and isomers, prodrugs, solvates, stable isotopic derivatives or pharmaceutically acceptable salts thereof. The present invention also relates to use of the compound in treating or preventing diseases mediated by TRK, such as cancers, and method for treating such diseases using the compounds of the present invention.

Heterocyclic compound as TRK inhibitor

The present invention relates to a heterocyclic compound, a pharmaceutical composition containing the same, a preparation method thereof, and use thereof as a fibroblast growth factor receptor (FGFR) inhibitor. The compound is a heterocyclic compound as shown in Formula I, or a pharmaceutically acceptable salt, prodrug, solvent compound, polymorph, isomer or stable isotopic derivative thereof. The present invention further relates to use of the compound for the treatment or prevention of related diseases which are FGFR-mediated such as cancer, and a method for applying the compound to treat said diseases.

Growing community of inventors

Nanjing, China

Zhixiang Zheng